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Abstract: Radiation-induced fibrosis (RIF) is a serious, yet incurable, complication of external beam 
radiation therapy for the treatment of cancer. Macrophages are key cellular actors in RIF because of 
their ability to produce reactive oxidants, such as reactive oxygen species (ROS) and inflammatory 
cytokines that, in turn, are the drivers of pro-fibrotic pathways. In a previous work, we showed that 
phagocytosis could be exploited to deliver the potent natural antioxidant astaxanthin specifically to 
macrophages. For this purpose, astaxanthin encapsulated into µm-sized protein particles could spe-
cifically target macrophages that can uptake the particles by phagocytosis. In these cells, astaxanthin 
microparticles significantly reduced intracellular ROS levels and the secretion of bioactive TGFβ 
and increased cell survival after radiation treatments. Here we show that pentoxifylline, a drug 
currently used for the treatment of muscle pain resulting from peripheral artery disease, amplifies 
the effects of astaxanthin microparticles on J774A.1 macrophages. Combination treatments with 
pentoxifylline and encapsulated astaxanthin might reduce the risk of RIF in cancer patients. 
Keywords: pentoxifylline; astaxanthin; particle encapsulation; oxidative stress; ionizing radiations; 
macrophages; radiation-induced fibrosis 
 
1. Introduction 
Radiation-induced fibrosis (RIF) is the most common long-term complication in can-
cer radiotherapy, and it affects a significant proportion of the ~60% cancer patients that 
receive radiation as part of their therapeutic regimens [1]. The onset of RIF occurs between 
1–4 months and 1–2 years after radiotherapy and it progresses in severity with time [2]. 
RIF does not regress spontaneously, and to date, there are no effective treatments for RIF 
prevention and/or treatment [3]. Investigations with patients and experimental animals 
have demonstrated a significant reduction of RIF with antioxidant treatments adminis-
tered after radiation [4]. The pathogenesis of RIF is still not fully understood, although it 
is known that phagocytic cells, such as macrophages, play a key role in RIF for their ability 
to produce oxidant chemical species, in particular reactive oxygen species (ROS), and in-
flammatory molecules that in turn trigger the fibrotic pathways in injured tissues [5]. 
Pentoxifylline (3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione , PTX) is a derivative of 
xanthine. PTX was approved by FDA in 1984 for the treatment of muscle pain resulting 
from peripheral artery disease, but it is also used off-label for the treatment of leg ulcers 
[6]. Indeed, PTX is known to improve the rheological properties of blood and wound heal-
ing, and to have anti-inflammatory and antioxidant activity [7]. 
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PTX has also been investigated as a radioprotector in vitro and in vivo because it can 
increase blood flow and tissue oxygenation upon oral administration [8]. It has provided 
satisfactory results in terms of RIF resolution but only at high doses (i.e., 800 mg/day over 
a 6-month treatment period [8]) that are not tolerated by patients and that can cause, 
among the side effects, serious gastrointestinal disorders [8,9]. Thus PTX alone cannot be 
used to cure RIF. Vitamin E is a well-known antioxidant, and it can effectively scavenge 
reactive oxygen species produced by radiation treatments. Moreover, its deficiency is as-
sociated with dysfunction of connective tissue repair [9]. When administered orally to pa-
tients its effects on RIF were only modest, but given in combination with PTX tablets, 
significantly reduced fibrosis and related clinical symptoms such as skin tightness, dysp-
nea, and pain [2]. 
Astaxanthin (ASX) is a xanthophyll ketocarotenoid with an antioxidant potential 100 
times higher than vitamin E [10]. We previously explored in vitro whether ASX could be 
effective against RIF [11]. ASX was encapsulated into µm-sized protein particles that can 
only be taken up by cells through phagocytosis, and in this way, we could target them 
specifically to macrophages [11]. In these cells, ASX microparticles significantly reduced 
intracellular ROS levels and, importantly, the secretion of bioactive transforming growth 
factor β (TGFβ) [11]. The role of this pro-inflammatory cytokine is central to fibrosis be-
cause it promotes fibroblasts recruitment, and local deposition of extracellular matrix 
components [12]. In addition, it inhibits the expression of antioxidant enzymes in target 
cells, further contributing to intracellular ROS accumulation [12]. 
Given these encouraging results and the outcomes of combination treatments with 
PTX and vitamin E discussed above, we explored whether PTX could also enhance the 
effects of ASX when given in combination to macrophages. We found that PTX could in-
deed improve the antioxidant and radio-protective activities of ASX microparticles. 
2. Results 
Full details concerning the synthesis of ASX-loaded microparticles along with their 
complete biochemical and biological characterization have been given in reference [11]. In 
this work we used the same preparations and in this section we describe new data con-
cerning PTX and its interactions with ASX microparticles. 
2.1. Cytotoxicity of PTX on J774A.1 Macrophages 
In our previous work, we showed that ASX microparticles were not cytotoxic for 
J774A.1 macrophage cells [11]. To the best of our knowledge no information is available 
on the safety of PTX in this cell system. We therefore assayed whether PTX could alter the 
growth kinetics of these cells. Intracellular ATP content was measured at different time 
points of the growth curve obtained with independent cell populations continuously ex-
posed to different PTX concentrations, and the results are shown in Figure 1. 
The data show that PTX, at all assayed concentrations, was not cytotoxic for J774A.1 
cells. 




Figure 1. Growth kinetics of J774A.1 cells exposed to different concentrations of PTX. The drug was 
administered to the cells at the indicated final concentrations at the beginning of the growth assays, 
and ATP was then measured. Cell populations were also left untreated as controls (black circles 
marked as ctrl). The error bars correspond to calculated standard errors and are not clearly visible 
in this figure because they are masked by the symbols (min. and max. coefficient of variation, 
CV=100*SE/mean, 0.75% and 6.0%, respectively). 
2.2. PTX Does Not Alter Phagocytosis of ASX-Loaded Microparticles 
Central to our treatment strategy is the idea that antioxidant molecules can be deliv-
ered specifically to macrophages (and other phagocytes) if loaded into particles of appro-
priate size that can be taken up by these cells through phagocytosis (see also our analyses 
carried out by confocal microscopy and reported in [11]). PTX has been reported to inhibit 
the phagocytosis induced by latex particles (~0.8 µm diameter) in monocytes and poly-
morphonuclear leukocytes in a dose-dependent manner. The critical PTX concentration at 
which the inhibitory activity became significant was 10 µg/mL [13]. We therefore assayed 
whether a slightly lower PTX concentration, namely 8 µg/mL, could inhibit phagocytosis 
of ASX microparticles in J774A.1 cells. 
Figure 2 shows that 8 µg/mL PTX did not inhibit phagocytosis of ASX microparticles 
in J774A.1 macrophages. 
 
Figure 2. Phagocytosis kinetics of ASX microparticles. The cells were exposed to ASX microparticles 
(P-ASX) and were either treated or left untreated with PTX at a final concentration of 8 µg/mL. 
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Phagocytosis was measured by flow cytometry thanks to the fluorescence emission of the ASX-con-
taining oleoresin encapsulated into the protein particles. In this figure cell autofluorescence of control 
untreated cells (ctrl) or of cells treated with PTX only is also shown. Values are given as mean ± SE. 
The error bars correspond to calculated standard errors and are not clearly visible in this figure 
because they are masked by the symbols (min. and max. coefficient of variation, CV=100*SE/mean, 
0.45% and 5.1%, respectively). 
2.3. Effects of PTX and ASX Microparticles on Intracellular ROS Levels 
PTX has been reported to have antioxidant activity [7], and more importantly to have 
a synergic effect with other antioxidants, such as vitamin E, in combined treatments [14]. 
We previously showed that ASX microparticles could significantly reduce intracellular 
ROS levels in J774A.1 cells treated with H2O2 to induce oxidative stress [11], and we there-
fore wondered whether PTX could also improve the effects of ASX particles. Figure 3 
shows that the intracellular ROS levels in J774A.1 macrophages decreased when PTX and 
ASX microparticles were given alone or in combination. 
 
Figure 3. Effects of PTX and ASX-loaded microparticles on intracellular ROS as evaluated by flow 
cytometry with the DCF-DA probe. Cell fluorescence was almost equal for untreated cells (cell au-
tofluorescence, ctrl) or cells treated with DCF-DA (probe), ASX microparticles (P-ASX), PTX or with 
P-ASX and PTX. Cell fluorescence significantly increased in cells loaded with DFC-DA and treated 
with H2O2, but treatments with PTX and ASX microparticles given alone or in combination signifi-
cantly suppressed the effects of H2O2 (see Figure 4 and Table 1 for statistical details). Data are the 
mean ± SE of 4 independent samples. 
Two-way ANOVA analyses indicated that PTX and ASX microparticles significantly 
interacted to reduce the intracellular ROS levels induced by hydrogen peroxide treatment 
in J774A.1 cells (Figure 4 and Table 1). 
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Table 1. Two-ways ANOVA analysis of the antioxidant effects of PTX and ASX microparticles given 
alone or in combination to J774A.1 cells. 
Treatment df 1 SS MS F p 
P-ASX 1 97.4 97.4 381.9 1.8 × 10−10 
PTX 1 122.1 122.1 478.9 4.9 × 10−11 
PTX and ASX 1 41.2 41.2 161.4 2.6 × 10−8 
Error 12 3.1 0.255   
Total 15 263.8    
1 df, degrees of freedom; SS, sum of squares; MS, mean squares. 
 
Figure 4. Graphical representation of the synergic effect of PTX and ASX microparticles on intracel-
lular ROS reduction in J774A.1 cells. The two lines would be expected to be parallel if there were no 
synergic effects [15]. Formally, synergism is demonstrated by two-ways ANOVA statistical analysis 
(see Table 1). 
2.4. Radical-Scavenging Activity of PTX and ASX-Containing Extract in a Cell-Free Assay 
Data in Figures 3 and 4 and Table 1 indicate that PTX is an intracellular ROS scaven-
ger. We further investigated its activity in a well-controlled cell-free assay, i.e., ABTS as-
say, in the attempt to explore whether the drug could react with free radicals on its own. 
As the control we used ASX-containing extracts that have an acknowledged antioxidant 
activity [16]. This result is somewhat expected since in a previous study PTX showed poor 
scavenging activity using DPPH assay [17]. This behavior is probably due to the lack of 
hydroxyl groups on PTX structure that underpin the scavenging activity of other potent 
antioxidants, such as vitamin E and phenolic compounds [18]. 
Figure 5 shows that PTX had no radical-scavenging activity at all assayed concentra-
tions. 





Figure 5. Antioxidant activity of PTX and ASX extracts in a cell free assay. (a) Antioxidant kinetics 
of ASX extracts compared to the spontaneous decay of ABTS cation radicals (ABTS+) in acetone 
solvent. (b) Antioxidant kinetics of PTX overlapped those of ABTS+· in acetone at all assayed con-
centrations. For the sake of clarity, in this panel we show only the final time-point, i.e., the measure-
ments carried out after 270 min for all PTX concentrations. 
We therefore concluded that the effects observed for PTX on intracellular ROS levels 
likely depend on the ability of the drug to activate cellular detoxifying pathways (see also 
Section 3 for further discussion on this point). 
2.5. Effects of PTX and ASX Microparticles on Irradiated Cells 
Ionizing radiations initiate oxidative stress in biological samples through water radi-
olysis that ultimately leads to cell death [19]. Since PTX and ASX microparticles cooper-
ated to significantly reduce intracellular ROS (Figures 3 and 4 and Table 1) we asked 
whether they could also increase the survival of irradiated cell samples when given alone 
or in combination to cells before radiation treatments. 
The clonogenic assay is commonly performed in radiobiology to quantify the radio-
sensitivity of cell samples. This test is based on the ability of cells to grow in isolation and 
form colonies [20], but in spite of several attempts we could not obtain well defined colo-
nies with J774A.1 cells (see also reference [11] for further discussion on this point). We 
therefore resorted to a recently developed method that translates into experiments a prob-
abilistic model of cell survival after radiotherapy and that is based on Poisson statistics 
[11,21]. The model is described by Equation (1) (see Section 4.8), and the final goal is to 
estimate the model parameter S(D) by nonlinear fitting of Equation (1) to experimental 
data. This parameter defines the survival probability of irradiated clonogenic cells. How-
ever, to univocally estimate its values an independent determination of the multiplicative 
parameter ε is required [11,21]. Parameter ε, on its turn, defines the clonogenic potential 
of non-irradiated cells and it can be precisely estimated using limiting dilution assays 
[11,21]. 
Figure 6 shows the results of our experiments with J774A.1 macrophages. ASX mi-
croparticles and PTX, given alone or in combination, did not alter significantly the clono-
genic potential of the J774A.1 cells (parameter ε) if compared to that of control untreated 
cells, but significantly increase the survival of irradiated cells (parameter S(D)). The sur-
vival of irradiated cells increased progressively when the cells were treated with ASX mi-
croparticles, PTX or ASX particles in combination with PTX. 





Figure 6. Effects of PTX and ASX microparticles on irradiated J774A.1 macrophages. (a) Limiting 
dilution assays were performed with non-irradiated cells to estimate parameter ε in Equation (1) 
(see the main text for details). Cells were seeded at each indicated density into the wells of 96-well 
culture plates and treated with ASX microparticles (P-ASX) and PTX, either alone or in combination 
(P-ASX + PTX), or left untreated (ctrl). F0 is the fraction of cells where no proliferation was observed 
at the end of the observation period (~30 days). When the cells are randomly and independently 
distributed, F0 is expected to obey Poisson statistics with parameter ε. Linear fitting of log-trans-
formed data provided the following estimates: εctrl = 0.328 ± 0.0325, εP-ASX = 0.336 ± 0.036, εPTX = 0.351 
± 0.036, εP-ASX+PTX = 0.364 ± 0.038. The differences in the estimated parameter values were not statis-
tically significant (ANOVA test, p = 0.9). (b) Survival probability of independent cell populations 
treated with ASX microparticles (P-ASX), PTX, P-ASX in combination with PTX (P-ASX + PTX) or 
left untreated (ctrl) and then irradiated with a dose of 4 Gy γ-rays. Nonlinear fits with Equation (1) 
allowed to estimate the fraction of the cells surviving radiation treatments (see also the main text 
for details). The results are: S(D)ctrl = 0.0071 ± 0.0005 (χ2/df = 1.5), S(D)P-ASX = 0.0086 ± 0.0006 (χ2/df = 
1.2), S(D)PTX = 0.0095 ± 0.0007 (χ2/df = 1.7), S(D)P-ASX+PTX = 0.0131 ± 0.001 (χ2/df = 2.1). All observed 
differences in estimated parameter values were statistically significant as evaluated by ANOVA (p 
= 1.5 × 10−12) followed by Tukey post-hoc test. 
3. Discussion 
Oxidative stress is involved in several diseases such as cancer, Alzheimer’s disease, 
Parkinson’s disease, atherosclerosis, heart failure, fibrosis and, in particular, RIF. It is a 
systemic pathologic condition caused by altered ROS accumulation in cells and tissues 
and hence by imbalance between ROS production and elimination through the activation 
of specific detoxifying mechanisms [22]. Ionizing radiations produce high amounts of 
ROS in both intracellular and extracellular compartments through water radiolysis [19]. 
This causes DNA lesions and other life-threatening damages not only to cancerous cells 
but also to irradiated and non-irradiated normal cells. It is nowadays accepted that radia-
tion generates “danger” signals that propagate from irradiated to non-irradiated cells (the 
so-called off-target effects). Such molecular signals include ROS, other reactive molecular 
species, cytokines, ATP and extracellular DNA [23]. These signals, in turn, activate im-
mune cells that, similar to macrophages, can further contribute to ROS production and 
can initiate and sustain the inflammatory cascade [23]. If uncontrolled, inflammation can 
cause tissue remodeling and dysfunction [24]. 
For example, the TGFβ cytokine promotes the recruitment of fibroblasts and local 
deposition of extracellular matrix components and it represents a key molecular actor in 
RIF [12]. 
RIF manifests in ~1/4 of all cancer patients that undergo radiotherapy with clinical 
consequences that impact the quality of their life [1]. Our previous study showed that ASX 
microparticles could not only reduce intracellular ROS levels in macrophages but also in-
hibited the secretion of bioactive TGFβ by these cells [11], indicating—although within 
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the limitations of a pre-clinical in vitro study—that the treatment strategy developed to 
target specifically phagocytic cells could indeed be effective. 
The results of the present study show that the effects of ASX microparticles can be 
further potentiated by combination treatment with PTX. PTX was nottoxic for the cells, 
did not interfere with phagocytosis of ASX microparticles, but at the same time could sig-
nificantly reduce the oxidative stress in J774A.1 macrophages. Cell-free assays, however, 
clearly showed that PTX had no direct antioxidant activity on its own. It has been reported 
that PTX may have indirect antioxidant effects in neutrophils where it may reduce the 
superoxide production via NADPH oxidase [7]. PTX has also been shown to contribute to 
the maintenance of GSH levels, mitochondrial viability and in general to have protective 
effects against malathion-induced oxidative damage to rat brain mitochondria in vivo 
[25]. The antioxidant activity of PTX, therefore, appears to depend on its ability to modu-
late intracellular detoxifying pathways. Our results are in line with this interpretation of 
the molecular mechanisms of action of PTX. Importantly, the drug showed synergistic 
antioxidant effects with ASX microparticles in J774A.1 cells and significantly contributed 
to increasing the survival of irradiated macrophages. These findings collectively show 
that both direct and indirect mechanisms can be activated to restore intracellular ROS lev-
els and protect cells from oxidative injury. 
PTX has also a well-acknowledged anti-inflammatory activity, since it can inhibit 
TNFα production and signaling [8]. Given in combination with ASX microparticles, that 
on their own inhibit active TGFβ release by targeted macrophages, might result in more 
effective treatments against inflammation and fibrosis. Overall, our previous and present 
observations justify further investigations with in vitro and in vivo models of fibrosis. 
4. Materials and Methods 
4.1. Pentoxifylline and Astaxanthin Loaded Microparticles 
Pentoxifylline P1784-100G powder was provided by Sigma-Aldrich (St. Louis, MO, 
USA). Astaxanthin Oleoresin (ASTAPure® 10% Oleoresin from Haematococcus pluvialis) 
was provided by Algatech (Ketura, Israel). 
The microencapsulation of astaxanthin oleoresin into the whey protein isolate shell 
was performed by emulsification and solvent evaporation technique described in the 
PCT/IB2019/05991 application. Chemical and physical properties (e.g., distribution of par-
ticles size, storage stability, absorption spectra) of astaxanthin loaded microparticles were 
given in our previous work [11]. The median particle size was ~2.5 µm. 
The concentration of ASX microparticles was expressed as µg of dried powder/mL 
of cell growth medium. The mass contribution of ASX into the microparticles is approxi-
mately 2.9%. Taking into account that the molecular weight of ASX is 596.8 g/mol this 
corresponds to a concentration of 48.6 nM ASX (µg/mL) dried particles. 
When not specified, in all assays the final concentration of PTX was 8 µg/mL (28.7 
mM). 
4.2. Cells and Cell Culture 
J774A.1 macrophages were obtained from the European Collection of Authenticated 
Cell Cultures (ECACC, Salisbury, UK; ECACC number 91051511). Murine macrophages 
were cultured in RPMI 1640 medium supplemented with foetal bovine serum (FBS), 10 
mg/mL gentamicin (Biochrom) and 2 mM glutamine (Sigma-Aldrich, St. Louis, MO, USA) 
at 37 °C in a humidified 5% CO2 atmosphere. 
Cell morphology was routinely checked using an Evos (AMG, Life Technology) dig-
ital inverted microscope and an Olympus IX51 (Olympus Corporation, Corporate Park-
way Center Valley, PA, USA) inverted microscope. 
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4.3. Cytotoxicity Assay 
J774A.1 cells were seeded at 5000 cells/well in 96-wells culture plates in 200 µL RPMI 
medium containing different concentrations of PTX, from 1 µg/mL to 64 µg/mL. At each 
time point after treatments the intracellular ATP content was quantified using the Cell 
Titer Glo® Luminescent Cell Viability Assay (Promega, Milan, Italy) following the manu-
facturer’s specification. Luminescence was measured with an FLX800 Microplate reader 
(FLX800, Bio-Tek Instruments, Bad Friedrichshall, Germany). All measurements were car-
ried out at least in 4 replicates. 
4.4. Flow Cytometry 
A Guava easyCyte 5 flow cytometer (Merck Millipore, Billerica, MA, USA) was used. 
The instrument is equipped with a 488 nm, 20 mW, blue laser light. Light scattering is 
measured by means of a forward scatter (FSC) photodiode and a side scatter (SSC) pho-
tomultiplier. Three fluorescence channels, green, yellow, and red, allow to collect cell-as-
sociated fluorescence at the same time, thanks to the following filters: green, 525/30 filter; 
yellow, 583/26; red, 680/30. Instrument calibration was routinely carried out using the 
Guava EasyCheck kit (Merck Millipore, Billerica, MA, USA) following the manufacturer’s 
instructions. We routinely collected at least 5000 gated events for analysis. 
4.5. Phagocytosis Kinetics 
J774A.1 cells were seeded at 20,000 cells/well in six-wells plates. Cells were incubated 
at 37 °C with 56 µg/mL of ASX microparticles for different days, and at each time point, 
phagocytosis of the microparticles was analyzed by flow cytometry. In fact, ASX oleoresin 
emits red fluorescence around 600 nm when excited by a blue laser light. In parallel as-
says, the cells were also treated with 8 µg/mL PTX. 
4.6. Intracellular ROS Detection 
The cell-permeable and H2O2-sensitive 2′,7′-Dichlorofluorescein diacetate (DCF-DA) 
fluorescent probe (Sigma-Aldrich, St. Louis, MO, USA) was used to measure intracellular 
ROS levels. When the diacetate group is cleaved by intracellular esterases the probe is 
retained into the cells. 
Macrophages were seeded in six-well plates at 60,000 cell/wells in 3 mL of growth 
medium and treated with 56 mg/mL ASX particles, 8 µg/mL PTX or both for 5 h at 37 °C 
to allow phagocytosis. The cells were then washed twice with PBS 1×, and the medium 
was replaced with 500 µL of 50 µM DCF-DA. The cells were further incubated for 30 min. 
After washings with PBS 1× the cells were incubated for 30 min at 37 °C with 3 mL of a 
solution containing 2.5 mL of growth medium and 0.5 mL of 0.1% w/w hydrogen peroxide 
in PBS (0.017% H2O2 final concentration) to increase intracellular ROS levels and simulate 
oxidative stress. The fluorescence of the DCF-DA probe was then measured by flow cy-
tometry. 
4.7. Free Radical Scavenging: ABTS Test 
The free radical scavenging capacity of PTX was also studied using the ABTS radical 
cation de-colorization assay which is based on the reduction of ABTS+• radicals by antiox-
idants [17]. 
ABTS (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in PBS to reach a final con-
centration of 7.4 mM. ABTS radical cation (ABTS+•) was produced by a chemical reaction 
of ABTS with 2.6 mM potassium persulfate (Sigma-Aldrich St. Louis, MO, USA). The re-
action was carried out overnight, in the dark, and at room temperature. The ABTS+• solu-
tion was then diluted in methanol to reach an absorbance of 0.75 at 734 nm. A BioTek 
PowerWave HT, microplate spectrophotometer (BioTek Instruments, Inc., Winoosky, VT, 
USA) was used. 
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Different concentrations of PTX dissolved in acetone (Sigma-Aldrich St. Louis, MO, 
USA) (20 µL) were allowed to react with 200 µL of ABTS+• solution into the wells of a 96-
well microplate kept in the dark. Absorbance kinetics were measured at room tempera-
ture starting at 5 min after initial mixing. All solutions were used the same day of their 
preparation, and all determinations were carried out in triplicate. 
4.8. Irradiation of Cell Samples 
The cells were seeded at different densities into the wells of 96-well culture plates, 1 
plate for each assayed cell density, and treated with 56 µg/mL of ASX microparticles 
and/or with 8 µg/mL PTX. After 24 h cells were irradiated with a dose of 4 Gy using a 
Gammacell40 irradiator (Atomic Energy of Canada Limited, Kanata, ON, Canada) 
equipped with a 137Cs source. The dose rate was 0.6654 Gy/min and the measured uni-
formity was ±1.3% over the entire sample chamber. Both parameters are monitored by the 
Radiation Protection Service of the University of Verona. 
After ~20 days surviving cell populations were determined by careful microscopic 
inspection and counted. The number of wells containing survivors divided by the total 
number of seeded wells is an experimental estimate of the overall survival probability P 
of the cells at a given radiation dose, and this probability is expected to vary as the func-
tion of cell density μ as follows [11,21]: 
P = 1 − e−S(D) ε μ (1) 
where S(D) is the survival probability of the cells with self-renewing potential (i.e., clono-
gens) irradiated with a dose D, and ε is the fraction of clonogens in a population of μ cells 
on average. To quantify the effects of radiation the parameter S(D) was estimated by non-
linear fitting of experimental data with Equation (1) knowing the fraction of clonogens ε 
in the cell population. This fraction was determined in independent limiting dilution as-
says as described [11,21]. 
4.9. Statistics 
All assays were carried out in 3–4 replicates and repeated at least three times with 
different cell batches. Data were expressed as mean ± SE, where SE is the standard error 
of the mean. Statistical analyses and nonlinear regression were carried out using the soft-
ware Mathematica (v.12, Wolfram Research Inc., Champaign, IL, USA). The reduced χ2, 
i.e., χ2/df where df is the number of degrees of freedom, was used to determine the good-
ness of the nonlinear fits. 
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